Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pulmonx (LUNG)
NASDAQ:LUNG
Pulmonx (LUNG) Stock Price & Analysis
76 Followers
LUNG Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.11 - $14.84
Previous Close$9
Volume170.41K
Average Volume (3M)619.98K
Market Cap
$349.34M
Enterprise Value$273.78M
Total Cash (Recent Filing)$116.13M
Total Debt (Recent Filing)$40.57M
Price to Earnings (P/E)-5.9
Beta1.79
Next Earnings
Jul 30, 2024EPS Estimate
-$0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding38,815,760
10 Day Avg. Volume361,093
30 Day Avg. Volume619,975
Standard Deviation0.18
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)3.23
Price to Sales (P/S)18.53
Price to Cash Flow (P/CF)-7.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.75
Enterprise Value/Gross Profit5.39
Enterprise Value/Ebitda-6.95
Forecast
1Y Price Target
$16.67Price Target Upside85.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Pulmonx News
Bulls Say, Bears Say
Bulls Say
Earnings BeatPulmonx reported quarterly revenue of $19.3M, exceeding market expectations, signaling robust sales growth.
Gross Margin ImprovementGross margins for Pulmonx expanded significantly, highlighting increased profitability through efficient operations.
Strong Sales GuidanceManagement's projection for 2024 sales is optimistic, reflecting confidence in Pulmonx's continued market expansion.
Bears Say
Financial ForecastLUNG does not expect material revenue in Japan until 2026 due to the post-approval study it is required to conduct.
Management StabilityManagement changes create uncertainty with the CFO leaving the company and the new CEO being in his first CEO role.
Revenue OutlookOUS sales were down 11.9% year-over-year, with management not expecting a return to growth until after 2024.
---
Ownership Overview
10.68% Insiders
38.98% Mutual Funds
42.62% Other Institutional Investors
7.73% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
ProductionRisks related to the company’s ability to manufacture goods and services
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LUNG FAQ
What was Pulmonx’s price range in the past 12 months?
Pulmonx lowest stock price was $7.11 and its highest was $14.84 in the past 12 months.
What is Pulmonx’s market cap?
Currently, no data Available
When is Pulmonx’s upcoming earnings report date?
Pulmonx’s upcoming earnings report date is Jul 30, 2024 which is in 72 days.
How were Pulmonx’s earnings last quarter?
Pulmonx released its earnings results on May 01, 2024. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.47 by $0.11.
Is Pulmonx overvalued?
According to Wall Street analysts Pulmonx’s price is currently Undervalued.
Does Pulmonx pay dividends?
Pulmonx does not currently pay dividends.
What is Pulmonx’s EPS estimate?
Pulmonx’s EPS estimate is -$0.43.
How many shares outstanding does Pulmonx have?
Pulmonx has 38,815,760 shares outstanding.
What happened to Pulmonx’s price movement after its last earnings report?
Pulmonx reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.47. Following the earnings report the stock price went up 21.503%.
Which hedge fund is a major shareholder of Pulmonx?
Among the largest hedge funds holding Pulmonx’s share is PRIMECAP Management Co. It holds Pulmonx’s shares valued at 72M.
---
Pulmonx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.67 (85.22% Upside)
$16.67 (85.22% Upside)
Blogger Sentiment
Bullish
LUNG Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $128.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.05%
12-Months-Change
Fundamentals
Return on Equity
-46.17%
Trailing 12-Months
Asset Growth
-18.23%
Trailing 12-Months
Company Description
Pulmonx
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.
---
LUNG Earnings Call
Q1 2024
0:00 / 0:00
---
LUNG Stock 12 Month Forecast
Average Price Target
$16.67
▲(85.22% Upside)
Technical Analysis
Best Analysts Covering LUNG
1 Year
1 Year Success Rate
3/12 ratings generated profit
1 Year Average Return
-12.14%
reiterated a buy rating 19 days ago
Copying Joanne Wuensch's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -12.14% per trade.
---